One-third of the adolescent population in Western countries is now considered to be overweight or obese. The implications of this epidemic remain unclear but may well lead to an increased prevalence of cardiovascular disease and an erosion in the mortality and morbidity gains that have been apparent in the last few decades. To further explore […]
Category: Cardiovascular risk
Empagliflozin reduces cardiovascular mortality in Type 2 Diabetics
The prevalence of type 2 diabetes is increasing rapidly and represents a major risk factor for cardiovascular disease. Although glycemic control has been shown to reduce microvascular complications, the effect of glycemic control on macrovascular disease is more limited. Furthermore, some glucose lowering drugs have been associated with worse cardiovascular outcomes. Accordingly, ensuring the cardiovascular […]